Top

Published in:

01-12-2021 | Breast Cancer | Research article

Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters

Authors: Guohua Liang, Wenjie Ma, Yanfang Zhao, Eryu Liu, Xiaoyu Shan, Weiwei Ma, Dabei Tang, Liru Li, Xingjian Niu, Wenhui Zhao, Qingyuan Zhang

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Hand-foot syndrome (HFS) is a side effect of skin related to pegylated liposomal doxorubicin (PLD) application. Moderate to severe hand-foot syndrome (MSHFS) might have a serious impact on patients’ quality of life and treatment. However, information on risk factors for the development of MSHFS is still limited. To analyze the risk factors for PLD-induced MSHFS in breast cancer patients and constructed a logistic regression prediction model.

Methods

We conducted a retrospective analysis of breast cancer patients who were treated with a PLD regimen in the Tumor Hospital of Harbin Medical University from January 2017 to August 2019. A total of 26 factors were collected from electronic medical records. Patients were divided into MSHFS (HFS > grade 1) and NMHFS (HFS ≤ grade 1) groups according to the NCI classification. Statistical analysis of these factors and the construction of a logistic regression prediction model based on risk factors.

Results

A total of 44.7% (206/461) of patients developed MSHFS. The BMI, dose intensity, and baseline Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) levels in the MSHFS group, as well as good peripheral blood circulation, excessive sweat excretion, history of gallstones, and tumour- and HER2-positive percentages, were all higher than those in the NMHFS group (P < 0.05). The model for predicting the occurrence of MSHFS was P = 1/1 + exp. (11.138–0.110*BMI-0.234*dose intensity-0.018*baseline ALT+ 0.025*baseline AST-1.225*gallstone history-0.681* peripheral blood circulation-1.073*sweat excretion-0.364*with or without tumor-0.680*HER-2). The accuracy of the model was 72.5%, AUC = 0.791, and Hosmer-Lemeshow fit test P = 0.114 > 0.05.

Conclusions

Nearly half of the patients developed MSHFS. The constructed prediction model may be valuable for predicting the occurrence of MSHFS in patients.

Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE. Breast cancer in China. Lancet Oncol. 2014;15(7):e279–89. https://doi.org/10.1016/S1470-2045(13)70567-9.CrossRefPubMed

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Verma S, Dent S, Chow BJ, Rayson D, Safra T. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev. 2008;34(5):391–406. https://doi.org/10.1016/j.ctrv.2008.01.008.CrossRefPubMed

Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, Batter V, Ngalula-Kabanga E, Dittrich C, Piccart M. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer. 2006;42(7):882–7. https://doi.org/10.1016/j.ejca.2005.12.011.CrossRefPubMed

Gebbia V, Mauceri G, Fallica G, Borsellino N, Tirrito ML, Testa A, Varvara F, Colombo A, Ferrera P. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation. Oncology. 2002;63(1):23–30. https://doi.org/10.1159/000065716.CrossRefPubMed

Bielack SS, Erttmann R, Kempf-Bielack B, Winkler K. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur J Cancer. 1996;32a:1652–60.CrossRefPubMed

Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol. 2007;18(7):1159–64. https://doi.org/10.1093/annonc/mdl477.CrossRefPubMed

Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC, Lacouture ME. Grading dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events version 4.0. J Am Acad Dermatol. 2012;67(5):1025–39. https://doi.org/10.1016/j.jaad.2012.02.010.CrossRefPubMed

Von Moos R, Thuerlimann BJ, Aapro M, et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer. 2008;44(6):781–90. https://doi.org/10.1016/j.ejca.2008.01.028.CrossRef

10.

Tomita Y, Shinohara N, Yuasa T, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Uemura H, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol. 2010;40(12):1166–72. https://doi.org/10.1093/jjco/hyq146.CrossRefPubMed

11.

Hackbarth M, Haas N, Fotopoulou C, Lichtenegger W, Sehouli J. Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study. Support Care Cancer. 2008;16(3):267–73. https://doi.org/10.1007/s00520-007-0318-8.CrossRefPubMed

12.

O'Brien ME. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anti-Cancer Drugs. 2008;19(1):1–7. https://doi.org/10.1097/CAD.0b013e3282f14a00.CrossRefPubMed

13.

Baer MR, King LE, Wolff SN. Palmar-plantar erythrodysesthesia and cytarabine. Ann Intern Med. 1985;102(4):556. https://doi.org/10.7326/0003-4819-102-4-556_1.CrossRefPubMed

14.

Zuehlke RL. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica. 1974;148(2):90–2. https://doi.org/10.1159/000251603.CrossRefPubMed

15.

Bhasin S, Sunita GDK, Kataria SP, Saluja S, Sharma M. Chemotherapy-induced palmer planter erythrodysesthesia. J Assoc Physicians India. 2005;53:155–6.PubMed

16.

Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, Gabizon A. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol. 2000;136(12):1475–80. https://doi.org/10.1001/archderm.136.12.1475.CrossRefPubMed

17.

Mrozek-Orlowski ME, Frye DK, Sanborn HM. Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncol Nurs Forum. 1999;26(4):753–62.PubMed

18.

Jacobi U, Waibler E, Schulze P, Sehouli J, Oskay-Özcelik G, Schmook T, Sterry W, Lademann J. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol. 2005;16(7):1210–1. https://doi.org/10.1093/annonc/mdi204.CrossRefPubMed

19.

Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54(4):987–92.PubMed

20.

Lademann J, Martschick A, Kluschke F, Richter H, Fluhr JW, Patzelt A, Jung S, Chekerov R, Darvin ME, Haas N, Sterry W, Zastrow L, Sehouli J. Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy. Skin Pharmacol Physiol. 2014;27(2):66–70. https://doi.org/10.1159/000351801.CrossRefPubMed

21.

Ajgal Z, Chapuis N, Emile G, Cessot A, Tigaud JM, Huillard O, Boudou-Rouquette P, Fontenay M, Goldwasser F, Alexandre J. Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters. Cancer Chemother Pharmacol. 2015;76(5):1033–9. https://doi.org/10.1007/s00280-015-2875-8.CrossRefPubMed

22.

Gordinier ME, Dizon DS, Fleming EL, Weitzen S, Schwartz J, Parker LP, Granai CO. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin. Gynecol Oncol. 2006;103(1):72–4. https://doi.org/10.1016/j.ygyno.2006.01.031.CrossRefPubMed

23.

Tanyi JL, Smith JA, Ramos L, Parker CL, Munsell MF, Wolf JK. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer. Gynecol Oncol. 2009;114(2):219–24. https://doi.org/10.1016/j.ygyno.2009.04.007.CrossRefPubMed

24.

Ko EM, Lippmann Q, Caron WP, Zamboni W, Gehrig PA. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients. Gynecol Oncol. 2013;131(3):683–8. https://doi.org/10.1016/j.ygyno.2013.09.031.CrossRefPubMed

25.

La-Beck NM, Zamboni BA, Gabizon A, et al. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol. 2012;69(1):43–50. https://doi.org/10.1007/s00280-011-1664-2.CrossRefPubMed

26.

Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Kirschbrown WP, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris HA 3rd, Zamboni WC. Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. Int J Nanomedicine. 2015;10:1201–9. https://doi.org/10.2147/IJN.S62911.CrossRefPubMedPubMedCentral

27.

Zamboni WC, Strychor S, Maruca L, Ramalingam S, Zamboni BA, Wu H, Friedland DM, Edwards RP, Stoller RG, Belani CP, Ramanathan RK. Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. Clin Pharmacol Ther. 2009;86(5):519–26. https://doi.org/10.1038/clpt.2009.141.CrossRefPubMed

Title: Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters
Authors: Guohua Liang
Wenjie Ma
Yanfang Zhao
Eryu Liu
Xiaoyu Shan
Weiwei Ma
Dabei Tang
Liru Li
Xingjian Niu
Wenhui Zhao
Qingyuan Zhang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08028-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

miR-17-5p drives G2/M-phase accumulation by directly targeting CCNG2 and is related to recurrence of head and neck squamous cell carcinoma

Clinical characteristics and risk factors associated with Pneumocystis jirovecii infection in patients with solid tumors: study of thirteen-year medical records of a large cancer center

The PROCEM study protocol: Added value of preoperative contrast-enhanced mammography in staging of malignant breast lesions - a prospective randomized multicenter study

Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinoma

Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L)

Retraction Note: Flavonoids modulate multidrug resistance through wnt signaling in P-glycoprotein overexpressing cell lines

Keynote webinar | Spotlight on antibody–drug conjugates in cancer